Lanreotide studies: 110 papers with results
Page 2 of 3
Lanreotide has 908 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
- SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.
Hammel P · Therapeutic advances in medical oncology · 2024
Non-randomized trial · 4 results
- Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
Shimatsu A · Endocrine journal · 2021
Non-randomized trial · 9 results
- Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.
Dekker SEI · European journal of clinical investigation · 2024
Non-randomized trial · 1 result
- A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
Blot K · Patient related outcome measures · 2019
Non-randomized trial · 4 results
- Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty.
Frystyk J · Circulation · 1996
Non-randomized trial · 7 results
- Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P · Clinical endocrinology · 2000
Non-randomized trial · 11 results
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME · Endocrine-related cancer · 2016
Non-randomized trial · 8 results
- Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T · Clinical endocrinology · 2006
Non-randomized trial · 5 results
- Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.
Caron PJ · Clinical endocrinology · 2017
Non-randomized trial · 15 results
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Caplin ME · Endocrine · 2021
Non-randomized trial · 4 results
- The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M · The American journal of gastroenterology · 2000
Non-randomized trial · 4 results
- Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D · Cancer · 2000
Non-randomized trial · 13 results
- Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A · Endocrine journal · 2013
Non-randomized trial · 13 results
- Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
Maulard C · Cancer chemotherapy and pharmacology · 1995
Non-randomized trial · 8 results
- Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study.
Ito T · Asia-Pacific journal of clinical oncology · 2021
Non-randomized trial · 11 results
- Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2003
Non-randomized trial · 3 results
- Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL · Clinical endocrinology · 2007
Non-randomized trial · 15 results
- Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A phase II prospective multicentre study.
Lévy P · Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2004
Non-randomized trial · 1 result
- Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
Raderer M · International journal of oncology · 2000
Non-randomized trial · 12 results
- Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression.
Fiebiger WC · Scandinavian journal of gastroenterology · 2002
Non-randomized trial · 9 results
- Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis.
Schiedermaier P · Digestion · 2002
Non-randomized trial · 2 results
- Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Jenkins PJ · Clinical endocrinology · 2000
Non-randomized trial · 2 results
- Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
Cannavò S · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2001
Non-randomized trial · 11 results
- Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers.
Sobhani I · British journal of clinical pharmacology · 1996
Non-randomized trial · 3 results
- The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial.
Papadaki T · Retina (Philadelphia, Pa.) · 2003
Non-randomized trial · 6 results
- Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.
Kuhn JM · British journal of clinical pharmacology · 1994
Non-randomized trial · 7 results
- An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly.
Lin JD · Endocrine journal · 1999
Non-randomized trial · 5 results
- Effect of lanreotide, a somatostatin analogue, on urea synthesis in normal man.
Wolthers T · Clinical nutrition (Edinburgh, Scotland) · 1994
Non-randomized trial · 4 results
- Lanreotide in the treatment of patients with thyroid eye disease.
Krassas GE · European journal of endocrinology · 1997
Non-randomized trial · 2 results
- Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
Chahal HS · The Journal of clinical endocrinology and metabolism · 2012
Non-randomized trial · 5 results
- The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.
Eriksson B · Digestion · 1996
Non-randomized trial · 9 results
- Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.
Temmerman F · Alimentary pharmacology & therapeutics · 2013
Non-randomized trial · 6 results
- Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.
Zarogoulidis K · Lung cancer (Amsterdam, Netherlands) · 2012
Non-randomized trial · 6 results
- Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.
Meyer T · Journal of neuroendocrinology · 2022
Non-randomized trial · 3 results
- Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers.
Drewe J · Clinical pharmacology and therapeutics · 1999
Non-randomized trial · 6 results
- The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Chrispijn M · Alimentary pharmacology & therapeutics · 2012
Observational study · 4 results
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Grenader T · Anti-cancer drugs · 2020
Observational study · 1 result
- Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.
Pusceddu S · Cancers · 2021
Observational study · 2 results
- Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
Petersenn S · Pituitary · 2020
Observational study · 8 results
- Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME · The oncologist · 2019
Observational study · 4 results
- BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Mirakhur B · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2018
Observational study · 1 result
- Somatostatin 2A receptor-expressing presympathetic neurons in the rostral ventrolateral medulla maintain blood pressure.
Burke PG · Hypertension (Dallas, Tex. : 1979) · 2008
Animal study (in vivo) · rat · 3 results
- Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition.
Tan CK · Gastroenterology · 1995
Animal study (in vivo) · mouse · 1 result
- Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis.
Häyry P · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 1993
Animal study (in vivo) · rat · 6 results
- The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A · Gut · 2009
Animal study (in vivo) · mouse · 1 result
- A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.
Kidd M · Regulatory peptides · 2007
Ex vivo tissue · rat · 3 results
- Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC · The Journal of clinical endocrinology and metabolism · 2001
In vitro (cells) · 5 results
- Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC · The Journal of clinical endocrinology and metabolism · 2006
In vitro (cells) · 1 result
- Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Florio T · Clinical endocrinology · 2003
In vitro (cells) · 7 results
- IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease.
Kidd M · Neurogastroenterology and motility · 2009
In vitro (cells) · 2 results